Professor of Medicine at OHSU Knight Cancer Institute
Oncology
Dr. Tomasz M. Beer, MD
|
|
Give Review
Tomasz Beer is an expert in the field of Oncology. He went to Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is one of the top medical schools in the US. Johns Hopkins University School of Medicine has a rank of 3 in research and a 29 in primary care He has 5 awards "America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Portland Monthly Magazine" and "Fellow (FACP)". Tomasz Beer is also published. He has 98 publications published. The lastest publication: "Metastatic prostate cancer in 2015: The new and the old that is new again.' He accepts Medicare.
Publications
- Metastatic prostate Cancer in 2015: The new and the old that is new again.
- Health-Related Quality Of Life (Hrqol) Benefits Of Enzalutamide In Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc): An In-Depth Analysis Of Eq-5d...
- Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate Cancer: results from PREVAIL.
- Functional regulation of hypoxia inducible factor-1α by SET9 lysine methyltransferase.
- Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate Cancer.
- Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.
- Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Can...
- Pharmacotherapeutic management of metastatic, castration-resistant prostate Cancer in the elderly: focus on non-chemotherapy agents.
- Bevicizumab and thrombosis: Some answers but questions remain.
- Molecular pathways and targets in prostate Cancer.
- Resistance training reduces disability in prostate Cancer survivors on androgen deprivation therapy: evidence from a randomized controlled trial.
- Review of Exercise Studies in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy Calls for an Aggressive Research Agenda to Generate High-Quality Evidenc...
- Personalizing prostate Cancer therapy: The way forward.
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy.
- Sustained complete response to ctla-4 blockade in a patient with metastatic, castration-resistant prostate Cancer.
- Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate Cancer.
- Skeletal Response to Resistance and Impact Training in Prostate Cancer Survivors.
- Patterns and predictors of symptom incongruence in older couples coping with prostate Cancer.
- Sequencing therapy in advanced prostate Cancer: focus on sipuleucel-T.
- Feasibility, Acceptability and Findings from a Pilot Randomized Controlled Intervention Study on the Impact of a Book Designed to Inform Patients about Cancer Clinical...
- Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma.
- Quality of Life After Sipuleucel-T Therapy: Results From a Randomized, Double-blind Study in Patients With Androgen-dependent Prostate Cancer.
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate Cancer: results from an open-label, multicenter phase I/II study.
- The role of C-reactive protein in prostate Cancer.
- Prevalence of Pain and Analgesic Use in Men With Metastatic Prostate Cancer Using a Patient-Reported Outcome Measure.
- Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospec...
- Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism.
- Complete Biochemical (Prostate-specific Antigen) Response to Sipuleucel-T With Enzalutamide in Castration-resistant Prostate Cancer: A Case Report With Implications fo...
- Serum and dietary vitamin D and cardiovascular Disease risk in elderly men: a prospective cohort study.
- HIF1α protein stability is increased by acetylation at lysine - K709.
- Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate Cancer: a phase II study of the Department of Defense Prostate C...
- Feasibility of shutter-speed DCE-MRI for improved prostate Cancer detection.
- The Exercising Together project: Design and recruitment for a randomized, controlled trial to determine the benefits of partnered strength training for couples coping ...
- HDAC4 regulates HIF1{alpha} lysine acetylation and Cancer cell response to hypoxia.
- A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve...
- Prostate Cancer and vitamin d: what does the evidence really suggest?
- Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate Cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defen...
- A HIF-Regulated VHL-PTP1B-Src Signaling Axis Identifies a Therapeutic Target in Renal Cell Carcinoma.
- RANDOMIZED TRIAL OF AUTOLOGOUS CELLULAR IMMUNOTHERAPY WITH SIPULEUCEL-T IN ANDROGEN DEPENDENT PROSTATE Cancer.
- New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety.
- A phase II study of everolimus in combination with imatinib for previously treated advanced Renal carcinoma.
- Toward predictors of survival in castration-resistant prostate Cancer.
- Acupuncture for hot flashes in patients with prostate Cancer.
- Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate Cancer.
- ID1 enhances docetaxel cytotoxicity in prostate Cancer cells through inhibition of p21.
- Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate Cancer.
- Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate Cancer.
- C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate Cancer (CRPC): Confirmatory results.
- CCL2 is induced by chemotherapy and protects prostate Cancer cells from docetaxel-induced cytotoxicity.
- Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate Cancer.
- Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate Cancer previously treated with docetaxel-based the...
- Development of a second-generation antiandrogen for treatment of advanced prostate Cancer.
- Prostate Cancer-associated gene expression alterations determined from needle biopsies.
- Optimal timing of chemotherapy in androgen independent prostate Cancer.
- Department of Defense prostate Cancer clinical trials consortium: a new instrument for prostate Cancer clinical research.
- Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced Cancer.
- Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate Cancer previously treated with taxanes.
- The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate Cancer and regulates apoptosis and the cell cycle in LNCaP prostate Cancer cells.
- Long-term remission of metastatic small cell carcinoma of the Prostate.
- Phase II study of KOS-862 in patients with metastatic androgen independent prostate Cancer previously treated with docetaxel.
- The hazards of intermediate endpoints.
- Molecular alterations in Prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differ...
- Prostate Cancer survival is dependent on season of diagnosis.
- Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate Cancer.
- Innovations and challenges in prostate Cancer: summary statement for the 6th Cambridge Conference.
- Prostate specific antigen only androgen independent prostate Cancer: natural history, challenges in management and clinical trial design.
- Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate Cancer during first year of therapy.
- Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate Cancer.
- Adjuvant weekly docetaxel for patients with high risk prostate Cancer after radical prostatectomy: a multi-institutional pilot study.
- Assessment of prostate-specific antigen doubling time in prediction of prostate Cancer on needle biopsy.
- Predictors of overall and Cancer-free survival of patients with localized prostate Cancer treated with primary androgen suppression therapy: results from the prostate ...
- Parenteral estrogens for prostate Cancer: can a new route of administration overcome old toxicities?
- Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate Cancer.
- Views on physician-assisted suicide among family members of Oregon Cancer patients.
- A molecular correlate to the Gleason grading system for Prostate adenocarcinoma.
- Metastatic adenocarcinoma of Prostate in a healing sternotomy site.
- Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell Malignancies.
- Effect of calcitriol on Prostate-specific antigen in vitro and in humans.
- Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate Cancer.
- Classification and regression tree analysis for the prediction of aggressive prostate Cancer on biopsy.
- Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate Cancer.
- Testosterone loss and estradiol administration modify memory in men.
- Interest in physician-assisted suicide among Oregon Cancer patients.
- Androgen deprivation impairs memory in older men.
- Recursive partitioning for risk stratification in men undergoing repeat Prostate biopsies.
- Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with Cancer.
- High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate Cancer: a phase I/II study.
- Statins and prostate Cancer risk: a case-control study.
- Treatment of erectile dysfunction following therapy for clinically localized prostate Cancer: patient reported use and outcomes from the Surveillance, Epidemiology, an...
- Resistance of prostate Cancer cell lines to COX-2 inhibitor treatment.
- Improved detection of prostate Cancer using classification and regression tree analysis.
- In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid Tumors.
- Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate Cancer.
- Phase II study of transdermal estradiol in androgen-independent Prostate carcinoma.
- Prognostic value of anemia in newly diagnosed metastatic prostate Cancer: a multivariate analysis of southwest oncology group study 8894.
- Fine-needle aspiration diagnosis of plasmacytoma presenting as breast masses in a patient on estrogen therapy for prostate Cancer.
- Randomized study of high-dose pulse calcitriol or placebo prior to radical Prostatectomy.
Schools
Johns Hopkins University School Of Medicine
Oregon Health and Science University
Procedures Preformed
- Thoracentesis
Conditions Treated
- AdRenal Gland Cancer
- Anemia
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Portland Monthly Magazine
- Fellow (FACP)
Education
-
Oregon Health & Science University -
Johns Hopkins University School of Medicine
Drug Facts
| NPI NUMBER | 1669487179 | |
| NPPES Provider LastName | BEER | |
| NPPES Provider FirstName | TOMASZ | |
| NPPES Provider ZIPCode | 972393011 | |
| NPPES Provider State | OR | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 512.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1669487179 |
| Last Name Of The Provider | BEER |
| First Name Of The Provider | TOMASZ |
| View All |
Similar Doctors
|
Dr. Devon J. Webster, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rom S. Leidner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Merav Sendowski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason A. Taylor, MD |
|
Dr. Regan M. Look, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Edward W. Soo, MD
This Doctor is OpenDoctor Recommended.
|